iThe aims of the administrative core are to set and implement programmafic goals and operafing procedures ,or the overall research as well as facilitate communicafion between projects and cores. Moreover, the core will monitor and develop scientific exchanges among all invesfigators and the Internal and External Advisory Committees. This will provide monitoring for scientific progress;maintain a system for fiscal accountability;oversee confiict of interests;provide broad statisfical support, and assist in the planning, implementafion of experiments and interpretafion of data for publications, patent applicafions, and ulfimately a pathway towards clinical product development. Most importanfiy the core will serve to integrate research activifies ongoing between each of the projects and the scientific cores. Dr. H. Gendelman will serve to organize and implement all acfivifies and will be assisted by a program coordinator, Dr. R. L. Mosley and a scientific codirector. Dr. H. Fox. The biostatisfical core will be led by Dr. Jane Meza;an experienced biostafistical expert.

Public Health Relevance

Antiretroviral therapies are the mainstay for HIV/AIDS treatments. Drug access, adherence, compliance and untoward toxicifies remain commonplace and most notably for substance abusers. We posit that specific drug targefing to sites of acfive viral growth in a safe, extended-release injectable formula will improve disease outcomes and have profound posifive clinical outcomes for substance abusers.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
1P01DA028555-01A1
Application #
8016290
Study Section
Special Emphasis Panel (ZRG1-AARR-D (40))
Project Start
Project End
Budget Start
2010-07-15
Budget End
2011-04-30
Support Year
1
Fiscal Year
2010
Total Cost
$114,214
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
McMillan, JoEllyn M; Cobb, Denise A; Lin, Zhiyi et al. (2018) Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice. J Pharmacol Exp Ther 365:272-280
McMillan, JoEllyn; Szlachetka, Adam; Zhou, Tian et al. (2018) Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques. AIDS :
Montenegro-Burke, J Rafael; Woldstad, Christopher J; Fang, Mingliang et al. (2018) Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress. Mol Neurobiol :
Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410
Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26
Sillman, Brady; Bade, Aditya N; Dash, Prasanta K et al. (2018) Creation of a long-acting nanoformulated dolutegravir. Nat Commun 9:443
Forsberg, Erica M; Huan, Tao; Rinehart, Duane et al. (2018) Data processing, multi-omic pathway mapping, and metabolite activity analysis using XCMS Online. Nat Protoc 13:633-651
Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154
Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137
Guijas, Carlos; Montenegro-Burke, J Rafael; Warth, Benedikt et al. (2018) Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat Biotechnol 36:316-320

Showing the most recent 10 out of 141 publications